Delusional infestation treated with risperidone: a series of 27 patients
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Citação
CLINICAL AND EXPERIMENTAL DERMATOLOGY, v.49, n.4, p.364-367, 2024
Resumo
Background Patients with delusional infestation (DI) frequently refuse to be treated with psychoactive drugs. In the past, pimozide was commonly used as a first-line agent but is now prescribed more rarely. Risperidone was first used to treat DI in 1995. A recent review identified 12 studies that evaluated the use of risperidone in 43 patients with DI.Objectives To study the characteristics of and therapeutic results in patients with DI treated with risperidone at a university medical centre in Sao Paulo, Brazil.Methods We performed a retrospective study of patients with DI treated with risperidone at a dermatological university clinic since 2016. Records were reviewed for personal data and findings related to treatment.Results Twenty-seven patients were studied (20 women and 7 men). The maintenance dose of risperidone varied from 1 mg three times weekly to 8 mg daily. Control of symptoms was achieved in the majority of patients. A reduction in dosage due to side-effects was seen in four patients; risperidone had to be switched to another antipsychotic in three cases, despite a good response. Only one patient did not respond to risperidone.Conclusions Risperidone is an effective, well-tolerated and safe treatment for delusional parasitosis. Adequate follow-up is mandatory in order to obtain long-term control of symptoms. Patients with delusional infestation (DI) frequently refuse to be treated with psychoactive drugs. Risperidone was first used to treat DI in 1995. A recent review identified 12 studies evaluating risperidone, with a total of 43 patients with DI. We studied the characteristics and therapeutic results in 27 patients with DI treated with risperidone in a university medical centre in Sao Paulo, Brazil. Control of symptoms was achieved in the majority. Risperidone is an effective, well-tolerated and safe treatment for DI. Adequate follow-up is mandatory to obtain long-term control of symptoms.
Palavras-chave
Referências
- Ahmed A, 2022, BRIT J DERMATOL, V187, P472, DOI 10.1111/bjd.21668
- Brownstone Nicholas, 2022, Int J Womens Dermatol, V8, pe035, DOI 10.1097/JW9.0000000000000035
- Elmer MKB, 2000, J AM ACAD DERMATOL, V43, P683, DOI 10.1067/mjd.2000.106510
- GALLUCCI G, 1995, PSYCHOSOMATICS, V36, P578, DOI 10.1016/S0033-3182(95)71615-2
- Huber M, 2008, PROG NEURO-PSYCHOPH, V32, P1967, DOI 10.1016/j.pnpbp.2008.09.014
- Kimsey LS, 2016, ACTA DERM-VENEREOL, V96, P298, DOI 10.2340/00015555-2236
- Lepping P, 2010, CLIN EXP DERMATOL, V35, P841, DOI 10.1111/j.1365-2230.2010.03782.x
- Martins ACGP, 2016, INT J DERMATOL, V55, P864, DOI 10.1111/ijd.13004
- McPhie ML, 2022, J DERMATOL TREAT, V33, P709, DOI 10.1080/09546634.2020.1795061
- Nucifora FC, 2019, NEUROBIOL DIS, V131, DOI 10.1016/j.nbd.2018.08.016
- Pearson ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029908
- Reszke R, 2021, POSTEP DERM ALERGOL, V38, P144, DOI 10.5114/ada.2019.88464
- Nico MMS, 2022, ACTA DERM-VENEREOL, V102, DOI 10.2340/actadv.v102.677
- Wong Jillian W, 2013, Indian J Dermatol, V58, P49, DOI 10.4103/0019-5154.105309